Prospect of Using Cell Product for the Therapy of Skin Defects in Diabetes Mellitus

A. P. Lykov; N. A. Bondarenko; O. V. Poveshchenko; T. V. Miller; A. F. Poveshchenko; M. A. Surovtseva; N. P. Bgatova; V. I. Konenkov

doi:10.1007/s10517-017-3970-0

Prospect of Using Cell Product for the Therapy of Skin Defects in Diabetes Mellitus

作者: Lykov A.¹^,2, Bondarenko N.¹^,2, Poveshchenko O.¹^,2, Miller T.¹, Poveshchenko A.¹^,2, Surovtseva M.¹^,2, Bgatova N.¹, Konenkov V.¹
隶属关系:
1. Research Institute of Clinical and Experimental Lymphology
2. E. N. Meshalkin Research Institute of Circulatory Pathology, Ministry of Health of the Russian Federation
期: 卷 164, 编号 2 (2017)
页面: 266-268
栏目: Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
URL: https://journals.rcsi.science/0007-4888/article/view/239545
DOI: https://doi.org/10.1007/s10517-017-3970-0
ID: 239545

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
作者简介
参考
统计

详细

The effectiveness of autologous cell product in the therapy of skin burn wounds was studied in C57B1/6 male mice against the background of streptozotocin-induced diabetes mellitus. In animals with and without modeled diabetes mellitus, significant decrease in skin defect area was observed after single administration of the cell product (bone marrow multipotent mesenchymal stromal cells, fibroblasts or media conditioned by these cells).